PT  - JOURNAL ARTICLE
AU  - Sergio Fandos
AU  - Elisa Minchole
AU  - Ana Lasierra
AU  - Ana Simon
AU  - Carolina Panadero
AU  - Guillermo Hernandez
AU  - Francisco De Pablo
AU  - Sandra Garcia
AU  - Carlos Lapresta
AU  - Salvador Bello
TI  - Biomarkers and severity in community-acquired pneumonia (CAP)
DP  - 2012 Sep 01
TA  - European Respiratory Journal
PG  - P2525
VI  - 40
IP  - Suppl 56
4099  - http://erj.ersjournals.com/content/40/Suppl_56/P2525.short
4100  - http://erj.ersjournals.com/content/40/Suppl_56/P2525.full
SO  - Eur Respir J2012 Sep 01; 40
AB  - INTRODUCTIONTo evaluate the prognostic value of biomarkers in community-acquired pneumonia (CAP), we studied the correlations between C-reactive protein (CRP), procalcitonin (PCT), leukocyte count (WBC) and proadrenomedulin (proADM) with the widely used PSI severity score.MATERIAL AND METHODSWe prospectively studied 282 immunocompetent, adults patients hospitalized with CAP, calculated their PSI score and measured on admission the mentioned four blood biomarkers. Subsequently, we established the ROC curves to determine which of the biomarkers had a better discriminating power from mild CAP (PSI 1-3) to severe ones (PSI 4-5).RESULTSPCT and proADM significantly discriminated severe from mild CAP, although the area under curve was significantly higher for proADM (0.757 vs. 0.581). The other two biomarkers did not reach statistical significance.CONCLUSIONSProADM is a good predictor of CAP severity at the time of admission, and can be useful, with the clinical scores to identify severe CAP. This may help us to make decisions of patients site of care and management in the early hours.